石志安

比較混合療法與三合療法在幽門螺旋桿菌第一線藥物之成本效益分析 = Hybrid therapy versus triple therapy in the first line treatment of helicobacter pylori infection: a cost-effectiveness analysis by: 石志安 (Language materials, printed)